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Abstract
Background: Fibroblast apoptosis is a critical component of normal repair and the acquisition of an apoptosis-
resistant phenotype contributes to the pathogenesis of fibrotic repair. Fibroblasts from fibrotic lungs of humans and
mice demonstrate resistance to apoptosis induced by Fas-ligand and prior studies have shown that susceptibility to
apoptosis is enhanced when Fas (CD95) expression is increased in these cells. Moreover, prior work shows that Fas
expression in fibrotic lung fibroblasts is reduced by epigenetic silencing of the Fas promoter. However, the
mechanisms by which microenvironmental stimuli such as TGF-β1 and substrate stiffness affect fibroblast Fas
expression are not well understood.
Methods: Primary normal human lung fibroblasts (IMR-90) were cultured on tissue culture plastic or on
polyacrylamide hydrogels with Young’s moduli to recapitulate the compliance of normal (400 Pa) or fibrotic
(6400 Pa) lung tissue and treated with or without TGF-β1 (10 ng/mL) in the presence or absence of protein kinase
inhibitors and/or inflammatory cytokines. Expression of Fas was assessed by quantitative real time RT-PCR, ELISA
and Western blotting. Soluble Fas (sFas) was measured in conditioned media by ELISA. Apoptosis was assessed
using the Cell Death Detection Kit and by Western blotting for cleaved PARP.
Results: Fas expression and susceptibility to apoptosis was diminished in fibroblasts cultured on 6400 Pa substrates
compared to 400 Pa substrates. TGF-β1 reduced Fas mRNA and protein in a time- and dose-dependent manner
dependent on focal adhesion kinase (FAK). Surprisingly, TGF-β1 did not significantly alter cell-surface Fas expression,
but did stimulate secretion of sFas. Finally, enhanced Fas expression and increased susceptibility to apoptosis was
induced by combined treatment with TNF-α/IFN-γ and was not inhibited by TGF-β1.
Conclusions: Soluble and matrix-mediated pro-fibrotic stimuli promote fibroblast resistance to apoptosis by
decreasing Fas transcription while stimulating soluble Fas secretion. These findings suggest that distinct
mechanisms regulating Fas expression in fibroblasts may serve different functions in the complex temporal and
spatial evolution of normal and fibrotic wound-repair responses.
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Background
Fibroblast apoptosis is critical for the normal resolution
of wound repair. In contrast, fibrotic repair is character-
ized by the accumulation of apoptosis-resistant fibro-
blasts and the disruption of normal tissue architecture
due to excessive extracellular matrix (ECM) deposition
and remodeling. Increasing recognition that enhanced
fibroblast apoptosis can promote the resolution of estab-
lished fibrosis in the lungs and other organs highlights
the importance of understanding the complex mecha-
nisms that regulate fibroblast survival and apoptosis dur-
ing the evolution of normal and pathologic repair [1–5].
Fibroblast fate is determined by the integration of sig-
nals generated by cell-cell interactions, soluble mediators
in the microenvironment, and molecular and biomech-
anical inputs from the ECM which converge to modulate
the susceptibility of cells to apoptotic stimuli. When a
potential apoptotic stimulus is encountered by a cell, the
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ultimate execution of the apoptotic program depends on
stimulus strength, stimulus recognition, and the ability
of the triggered signaling cascade to overcome an array
of intrinsic inhibitors capable of blocking signal propa-
gation [6, 7]. Thus, the apoptotic susceptibility of a cell
at a given point in time represents a dynamic balance of
pro- and anti-apoptotic mechanisms that are tightly
regulated and can be skewed to favor either survival or
apoptosis.
The tumor necrosis factor (TNF) receptor superfamily
member Fas (CD95/Apo-1) serves a key function in the
recognition and transduction of apoptotic signals
through the extrinsic apoptosis pathway [6]. Fas ligand
(FasL) binding to aggregated transmembrane Fas trimers
promotes the assembly of the death-inducing signaling
complex (DISC) and the downstream activation of the
caspase cascade required for the execution phase of
apoptosis [6, 8]. Data from humans with lung fibrosis,
murine models of lung fibrosis, and cell culture systems
support a role for Fas/FasL interactions in the pathogen-
esis of fibrosis, although the definitive mechanisms
involved have not been determined [8–17]. FasL-
expressing inflammatory cells have been identified in the
bronchoalveolar lavage fluid and lung tissue of patients
with idiopathic pulmonary fibrosis (IPF) and epithelial
cells in IPF tissue were found to express Fas, suggesting
that Fas/FasL interactions can promote ongoing alveolar
epithelial cell death [18]. Additional studies confirmed
strong epithelial cell Fas expression in IPF tissue and
showed that myofibroblasts within fibroblast foci have
minimal Fas expression, a finding that highlights the
epithelial-fibroblast apoptosis paradox of IPF [8, 19, 20].
Furthermore, several studies have shown that fibroblasts
from patients with fibrotic lung diseases have increased
resistance to FasL-induced apoptosis, which would be
expected in cells with decreased Fas expression [14, 15,
17, 21, 22]. Importantly, however, fibroblast susceptibil-
ity to apoptosis can be enhanced by inducing cell mem-
brane Fas expression with exposure to inflammatory
cytokines [19].
We have shown that murine lung fibrosis is associated
with epigenetic suppression of the Fas promoter in lung
fibroblasts and that fibroblasts isolated from IPF lung
tissue have similar epigenetic modifications of the Fas
promoter [13]. Others have recently shown that the
resolution of bleomycin-induced fibrosis in mice corre-
lates with the apoptotic susceptibility of fibroblasts co-
cultured with FasL-expressing T-cells [7]. Although fi-
broblasts from fibrotic lungs express decreased levels of
Fas and have increased resistance to apoptosis, the
mechanisms by which pro-fibrotic stimuli regulate Fas
expression in fibroblasts have not been explored. Given
that TGF-β1 and matrix stiffness play key roles in acti-
vating fibroblasts and promoting fibroblast resistance to
apoptosis, we sought to determine how these factors
regulate Fas expression in normal lung fibroblasts.
Methods
Cell lines and culture
Normal primary human fetal (IMR-90) lung fibroblasts
were obtained from ATCC (Manassas, VA). Cells be-
tween passages 8 and 16 were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 5% fetal
bovine serum (FBS) to 60% confluence and growth
arrested for 16–24 h prior to treatment. Fibroblasts were
cultured on tissue culture plastic or on polyacrylamide
hydrogel substrates with stiffness of either 400 Pa or
6400 Pa. The polyacrylamide hydrogels were prepared in
the Tschumperlin laboratory and functionalized with
type 1 collagen as previously described [23].
Antibodies and reagents
Porcine TGF-β1, recombinant human tumor necrosis
factor alpha (TNF-α) and recombinant human interferon
gamma (IFN-γ) were from R&D Systems (Minneapolis,
MN). Cycloheximide was from Sigma (St. Louis, MO).
The activating anti-Fas antibody (clone CH11, desig-
nated as Fas-Ab) was from Millipore (Upstate, NY).
PF573228, which directly blocks FAK kinase activity
without significantly inhibiting PI3K or Rho-kinase
(ROCK) was from Tocris Bioscience (Ellisville, MO)
[24]. LY294002, (a PI3K inhibitor) was from Cell Signal-
ing Technology (Danvers, MA). Rabbit monoclonal anti-
bodies to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), and poly-(ADP-ribose) polymerase (PARP)
were from Cell Signaling (Danvers, MA; 1:1000 dilution
used). The rabbit polyclonal antibody to Fas used for
Western blots was from Novus Biologicals (Littleton,
CO; 1:1000 dilution). The Cell Death Detection ELISA
Kit detecting histone-associated DNA fragments was
from Roche Applied Science (Indianapolis, IN). Horse-
radish peroxidase–conjugated secondary antibodies were
from Pierce (Rockford, IL).
Western immunoblot analysis and densitometry
Whole cell lysates were subjected to SDS-PAGE and
Western blotting as previously described [24]. All West-
ern blots were stripped and re-probed for GAPDH. Band
densities were analyzed using the public domain NIH
ImageJ program version 1.50i available at http://rsbweb.
nih.gov/ij. The ratio of the band density for the target
protein and for the corresponding GAPDH was deter-
mined and indexed such that the average expression in
untreated controls was 1.0 and differences in expression
represent “fold change”.
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Quantitative real-time RT-PCR
Quantitative real-time RT-PCR was performed using
StepOne Plus Real Time PCR Systems by Applied Bio-
systems (Foster City, CA). Relative quantitation was
based on the ΔΔCT method. We used the human Fas
cell surface death receptor, FAS gene (Hs00236330_m1)
primer probe set and the housekeeping gene ACTB
(Hs99999903_m1) from ThermoFisher Scientific (Ann
Arbor, MI).
Flow cytometry
Cells were collected by scraping and incubated with Fc
Block (1:100) clone 24G2 (BD Pharmingen, San Diego,
CA) for 15 min, then stained with propidium iodide,
FITC Mouse Anti Human CD95 (Clone DX2) or FITC
Mouse IgG1 Isotype Control, (Clone MOPC-21) anti-
bodies (BD Pharmingen) for 30 min. Cells were run on a
FACS Canto (BD Biosciences, Mountain View, CA) and
further analyzed using the Flowjo single cell software
analysis software.
Fas ELISA
A 96-well MaxiSorp Immuno Plate (ThermoFischer Sci-
entific, Ann Arbor, MI) was coated with 2 μg/ml Fas
capture antibody (MAB144) from R&D Systems (Minne-
apolis, MN) and incubated overnight at 4 degrees Cel-
sius. The coated plate was washed and blocked with
casein in PBS for 1 h. After washing, samples and re-
combinant standards (326-FS-050 from R&D Systems,
Minneapolis, MN) were loaded and incubated at room
temperature for 2. After washing, the plate was incu-
bated with 0.1 μg/ml Fas detection/biotinylated antibody
(BAF 326, R&D Systems, Minneapolis, MN) for one
hour and washed. Substrate development was done with
peroxidase–conjugated streptavidin solution (Jackson
ImmunoReserach Labs Inc., West Grove, PA) for
30 min. The plate was washed and color developed with
3, 3′, 5, 5’-Tetramethylbenzidine in 0.1 M acetate buffer
with hydrogen peroxide (all from Sigma) for 20 min. Re-
action was stopped with sulfuric acid. Absorbance was
read at 450 nm. Data was analyzed SpectraMax M3 Sof-
Max Pro 5 (Molecular Devices, Sunnyvale, CA).
Cell surface immunofluorescence staining
20,000 fibroblasts per well were seeded on polystyrene
glass slides (Falcon Brand) and cultured for 24 h prior to
growth arrest in serum-free media for another 24 h prior
to treatment with/without TGF-β1 (10 ng/ml) for 24 h.
Cells were fixed (without permeabilization) in 4% para-
formaldehyde for 30 min and non-specific binding was
blocked with 3% bovine serum albumin for 1 h prior to
sequential incubation with rabbit polyclonal anti-Fas
antibody (Novus Biologicals catalog # NBP1–89034) at
1:50 dilution for 16 h (4 °C) and then a FITC-labeled
secondary antibody (Invitrogen) at a 1:200 dilution for
1 h (room temperature). Nuclei were stained with DAPI.
Fluorescence intensity was measured with NIH Image J
and quantified as the “corrected total cell fluorescence”
as previously reported [25].
Statistical analysis
Statistical analysis was done using GraphPad Prism ver-
sion 6.01. Comparisons for experiments with more than
two conditions were made using one-way ANOVA with
Tukey’s multiple comparisons test. Comparisons be-
tween two cohorts were done using an unpaired t-test.
Data shown are the mean ± standard error of the mean.
Each figure legends report the numbers of independent
experimental replicates represented in each figure.
Results
Fibroblast susceptibility to apoptosis and expression of
Fas are reduced on stiff substrates
Biochemical and biomechanical properties of the extra-
cellular matrix significantly impact fibroblast phenotypes
including basal rates of apoptosis [26]. To determine
whether substrate stiffness impacted fibroblast suscepti-
bility to apoptosis triggered by activation of the extrinsic
pathway, normal lung fibroblasts cultured on polyacryl-
amide hydrogels with the compliance of normal lung
parenchyma (400 Pa) or on hydrogels that recapitulate
the stiffness of fibrotic lung tissue (6400 Pa) were treated
with/without a Fas-activating antibody (Fas-Ab, 250 ng/
ml) [23]. Supporting a key role for increased matrix stiff-
ness supporting an apoptosis-resistant fibroblast pheno-
type, cells cultured on the compliant (400 Pa) substrates
were more susceptible to Fas-induced apoptosis than
those cultured on the more rigid (6400 Pa) substrates
(Fig. 1a). We observed no significant differences in
susceptibility to Fas-mediated apoptosis with further in-
creases in substrate stiffness, including glass substrates
(Additional file 1: Figure S1).
Others have shown that fibroblast susceptibility to
Fas-ligand induced apoptosis can be regulated by enhan-
cing cell surface Fas expression and that apoptosis-
resistant fibroblasts from patients with fibrotic lung dis-
ease have decreased cell-surface Fas expression [14, 19].
To determine the effect of substrate stiffness on Fas ex-
pression, normal lung fibroblasts were seeded in serum-
free media on 400 or 6400 Pa substrates for 24 h. Both
Fas mRNA and protein were significantly decreased in
cells on the 6400 Pa substrate (Fig. 1b and c).
TGF-β1 reduces Fas expression in normal lung fibroblasts
on stiff substrates
TGF-β1 is a pro-fibrotic cytokine that promotes fibro-
blast resistance to apoptosis and is activated, in part,
through non-proteolytic mechanisms that are dependent
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on substrate stiffness [27]. Consistent with a necessary
role for increased substrate stiffness, we found that
TGF-β had no significant effect on Fas expression when
fibroblasts were cultured on compliant (400 Pa) poly-
acrylamide hydrogels (Additional file 1: Figure S2). To
evaluate the effect of TGF-β1 on fibroblast Fas expres-
sion on stiff substrates, we measured Fas mRNA and
protein in response to different doses and durations of
TGF-β1 treatment (Fig. 2). First, we found that low-dose
TGF-β1 (2 ng/ml) failed to significantly impact Fas tran-
scription over 48 h, but a higher dose (10 ng/ml) that is
commonly used to study fibroblast behavior [28, 29]
induced a time-dependent decrease in Fas mRNA that
was significant at 24 h and persisted at 48 h (Fig. 2a and
b). Using Western blot, we observed a small but signifi-
cant decline in Fas over 24 h with the 2 ng/ml dose and
a more pronounced decline at 24 h following treatment
with 10 ng/ml (Fig. 2c and d). To improve the sensitivity
of our assessment, we also measured total Fas in whole
cell lysates (“cellular Fas”) using ELISA (Fig. 2e and h).
With this method, we did detect a statistically significant
decline in Fas with 2 ng/ml which was accentuated with
the 10 ng/ml dose of TGF-β1. Finally, we confirmed the
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Fig. 1 a Normal lung fibroblasts were cultured on polyacrylamide substrates with Young’s moduli of 400 Pa or 6400 Pa for 24 h in serum-free
media prior to treatment with/without the Fas-activating antibody (Fas-Ab, 250 ng/ml) for 16 h, and apoptosis was assessed using ELISA detection
of histone-associated DNA-fragments. The figure represents pooled data from five independent experiments with 3 technical replicates included
in each experiment, with the data for each independent experiment normalized to 400 Pa controls to allow comparisons. *** p < 0.001 compared
to untreated cells on 400 Pa. Comparisons were made using one-way ANOVA with Tukey’s multiple comparison test. b Fas mRNA in normal
fibroblasts cultured for 24 h on 400 or 6400 Pa substrates was assessed by quantitative real-time RT-PCR. n = 3 independent experiments with
two technical replicates per experiment, with data normalized to the average expression in cells on the 6400 Pa substrates. * p < 0.05 using
unpaired T-test. c Fas protein in cell lysates was measured by ELISA. Data pooled from 3 independent experiments. Fas concentration was
determined as pg Fas/μg protein collected and was then normalized to the average concentration of 6400 Pa substrates to allow direct
comparisons between experimental replicates. * p < 0.05 using unpaired T-test




















0 4 8 24 48 Time (h)





















0 4 8 24 48 Time (h)

































0 4 8 24 Time (h)

































0 2 5 10

























Time (h)0 4 8 24





























Time (h)0 4 8 24






























0 4 8 24 Time (h)
TGF- 1 (2 ng/ml)
**
*
Fig. 2 Normal lung fibroblasts were grown on tissue culture plastic in DMEM supplemented with 5% FBS to 60% confluence, serum deprived for 24 h in
DMEM without serum and then treated with/without TGF-β1 at the indicated doses and durations. a and b Fas mRNA determined by quantitative real-
time RT-PCR (qPCR); pooled data with an “n” of at least 7 independent replicates for each dose and time point. c and d Representative Western blots for
Fas protein in whole cell lysates, with densitometric analysis. Densitometry represents data with at least 7 independent experimental replicates for each
dose at the 24-h time point and 4 independent replicates at the 4- and 8-h time points. * p < 0.05 and ** p< 0.01 compared to untreated controls (One-
way ANOVA with Tukey multiple comparison test). e and f Fas protein in whole cell lysates measured by ELISA. Data represent pooled results from at least
5 independent experimental replicates at the 24-h time points and 2–3 experimental replicates at the 4- and 8-h time points. ** p < 0.01 compared to
control (One-way ANOVA with Tukey multiple comparison test). g Representative Western blot and (h) densitometry for Fas. n = at least 5 independent
experimental replicates for each condition. *** p< 0.001 compared to untreated controls (One-way ANOVA with Tukey multiple comparison test)
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treated with 2, 5 or 10 ng/ml of TGF-β1 for 24 h via
Western blot (Fig. 2g) and ELISA (Fig. 2h). Based on the
clear and consistent suppression of Fas established in
these experiments, additional studies were done using
TGF-β1 at a dose of 10 ng/ml.
TGF-β1 suppression of Fas is dependent on FAK activity
Focal Adhesion Kinase (FAK) is a non-receptor tyrosine
kinase that is critical in mechanotransduction signaling,
is activated by TGF-β1, mediates myofibroblast differen-
tiation, promotes myofibroblast resistance to apoptosis,
and is necessary for lung fibrogenesis [30–33]. Having
found that both TGF-β1 and stiff ECM substrates sup-
press Fas expression in fibroblasts, we next examined
the role of FAK in this process. In fibroblasts treated
with the FAK inhibitor PF573228 [24], TGF-β1 failed to
suppress Fas mRNA expression (Fig. 3a). In contrast, in-
hibition of the pro-survival PI3K/AKT signaling pathway
with LY294002 had no impact on TGF-β1-mediated sup-
pression of Fas transcription (Fig. 3a). Consistently, FAK
inhibition mildly increased basal Fas expression and pre-
vented the TGF-β-mediated reduction in Fas protein
(Fig. 3b). Taken together, these experiments demonstrate
that FAK activation has a critical role in TGF-β1 stimu-
lated suppression of Fas in normal fibroblasts.
TGF-β induces the secretion of soluble Fas
Receptor expression represents the balance of protein synthe-
sis and degradation. However, Fas is a member of the TNF-
alpha superfamily, and studies have shown that these recep-
tors, including Fas itself, can be secreted from cells as a bio-
logically active soluble receptor [34]. Moreover, increased
concentrations of soluble Fas (sFas) have been reported in
the cell culture supernatants of fibrotic lung fibroblasts com-
pared to normal lung fibroblasts [14]. In concert with pro-
teins known to be secreted by fibroblasts, such as TIMP1
and TIMP2, we identified sFas in cell culture supernatants
from normal lung fibroblasts treated with TGF-β1 for 24 h
(Fig. 4a). Using ELISA, we confirmed that TGF-β1 treatment
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Fig. 3 Normal lung fibroblasts were pre-treated with/without the FAK inhibitor PF573228 (10 μM) or the PI3K inhibitor LY294002 (10 μM) for one
hour prior to treatment with TGF-β1 (10 ng/ml). Fas expression was then assessed by (a) qPCR; * p < 0.05 compared to untreated controls, n = 2
independent experimental replicates, (b) Western blot of whole cell lysates; representative blot with densitometry from three independent
experimental replicates. * p < 0.05 and ** p < 0.01 compared to untreated controls
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media between 8 and 24 h, and that there was a dose-
response effect to TGF-β1 (Fig. 4b). To determine if the sFas
in conditioned media represented the consequence of shed-
ding/cleavage of cell-surface receptors or if it was due to the
secretion of existing cytoplasmic Fas, we pre-treated cells for
one hour with Brefeldin-A, which inhibits protein transport
from the endoplasmic reticulum to the Golgi and thereby
blocks the protein secretory pathway. Supporting a role for
the secretory pathway, TGF-β1 failed to increase the sFas in
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Fig. 4 a Normal lung fibroblasts were treated with/without TGF-β1 (2 ng/ml) for 6 or 24 h (or were untreated controls). Proteins in the cell-culture
supernatants were qualitatively assessed with the RayBio Human Cytokine Antibody Array 7.1. Shown are the assay positive controls (upper left and
bottom right, black-dashed box), Fas/TNFRSF6 (red box) and TIMP1/2 (blue box). b sFas levels were assessed in the cell culture supernatants of normal
lung fibroblasts treated with/without TGF-β1 (2 or 10 ng/ml) for the indicated time points. Data shown have been pooled from at least 3 independent
experiments included with each dose- and time-point, and data have been indexed to represent the “fold-change” compared to the average of the
untreated fibroblasts. ** p < 0.01 and *** p < 0.001 vs. untreated controls. c sFas was measured in the conditioned media from fibroblasts were treated
+/− Brefeldin A (100 ng/ml) for 15–30 min then +/− TGF-β1 (10 ng/ml) for 24 h. Cell culture supernatants assessed for Fas by ELISA. Levels below assay
detection were censored to the lowest detected concentration. The data shown are from 3 independent experiments. d Normal fibroblasts were
treated with/without TGF-β1 (10 ng/ml) for 24 h. After washing, intact cells were collected by scraping and subjected to flow cytometry for Fas. A
representative histogram is shown (left) along with the mean fluorescence intensity of untreated and TGF-β1 treated cells (right). n = 3 independent
experiments. The gating strategy used is shown in Supplemental Data Fig. 3. e Cell-surface Fas immunofluorescence staining in normal lung fibroblasts
treated with or without TGF-β1 (10 ng/ml) for 24 h. f Fluorescence was quantified in 10 individual cells per condition (5 cells from each of two
independent experimental replicates)
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Brefeldin-A (Fig. 4c). Consistent with secretion of Fas as the
primary mechanism underlying decreased fibroblast Fas, we
used flow-cytometry to demonstrate that TGF-β1 did not sig-
nificantly alter cell-surface Fas expression at 24 h (Fig. 4d).
Similarly, there was no significant difference observed in cell-
surface Fas expression when assessed by immunofluores-
cence staining (Fig. 4e and f).
Augmented fibroblast susceptibility to apoptosis induced
by treatment with IFN-γ and TNF-α is maintained despite
treatment with TGF-β1
Fibroblast susceptibility to Fas-induced apoptosis is en-
hanced by increased cell surface Fas expression induced
by combined treatment with TNF-α and IFN-γ [15, 19].
Prior studies from our laboratory have shown that TGF-
β1 reduces fibroblast susceptibility to Fas-mediated
apoptosis through activation of pro-survival protein kin-
ase signaling pathways and up-regulation of intracellular
inhibitors of apoptosis [4, 21, 35]. Having now shown
that TGF-β also reduces fibroblast expression of Fas we
sought to determine whether the anti-apoptotic effects
of TGF-β1 would counter the effects of TNF-α and IFN-
γ and reverse the enhanced sensitivity to apoptosis sensi-
tivity afforded by these inflammatory cytokines. To ad-
dress this, we treated normal lung fibroblasts with the
combination of TNF-α and IFN-γ for between 0 and
48 h (cells treated for less than 48 h were washed with
PBS and maintained in serum-free media for the
remaining time until completion of the 48-h period).
After 48 h, the cells were washed and treated with or
without TGF-β1 for an additional 24 h, so that all of the
cells were in culture for the 72-h duration of the experi-
ment. Consistent with prior studies, fibroblasts exposed
to the inflammatory cytokines for at least 8 h showed
enhanced Fas expression which peaked at 24 h and per-
sisted in the absence of TGF-β1 for the entire 72-h dur-
ation of the experiment (Fig. 5a) [15]. Interestingly, the
cells treated with the inflammatory cytokines for 24 or
48 h followed by TGF-β1 for 24 h had no significant de-
cline in cellular Fas. Next, we treated fibroblasts with the
combination of inflammatory cytokines for 24 h prior to
exposure to Fas-activating antibody alone or in combin-
ation with TGF-β1 and assessed apoptosis by Western
blot for identification of cleaved PARP. The combination
of cytokines alone was not sufficient to induce apoptosis,
but apoptosis was apparent in cells treated with the
combination of cytokines and Fas-activating antibody.
Consistent with cellular Fas-expression impacting sus-
ceptibility to apoptosis, TGF-β1 failed to decrease the
susceptibility to apoptosis in the cells that had been pre-
treated with inflammatory cytokines (Fig. 5b). Collectively,
these findings indicate that TGF-β1 does not antagonize
the increase in cell surface Fas induced by inflammatory
cytokines. Moreover, the increased susceptibility to
Fas-induced apoptosis afforded by treatment with the
inflammatory cytokines is not altered by TGF-β1, suggest-
ing that increasing cell-surface expression of Fas is suffi-
cient to overcome the non-Fas mediated anti-apoptotic
mechanisms induced by TGF-β1.
Discussion
Fibroblast apoptosis heralds the resolution phase of nor-
mal repair while fibroblast resistance to apoptosis con-
tributes to the progressive scar formation that
characterizes fibrosis in the lungs and other organs. In
recent years, a number of mechanisms involving inhibi-
tor of apoptosis family proteins, BCL-2 family proteins,
pro-survival protein kinase activation and cell-matrix in-
teractions have been shown to regulate fibroblast sus-
ceptibility to apoptosis and accumulating studies
demonstrate the feasibility of targeting fibroblast survival
as a treatment strategy for fibrotic disease in the lung [1,
4, 21, 24, 36, 37]. Additionally, several studies now indi-
cate that regulation of Fas itself may contribute to fibro-
blast acquisition of an apoptosis-resistant phenotype,
although our understanding of the underlying mecha-
nisms continues to evolve [7, 16, 20, 38]. In the current
study, we have shown that pro-fibrotic soluble and
mechanical stimuli suppress fibroblast expression of Fas
through both transcriptional and post-transcriptional
mechanisms, that decreased Fas correlates with resist-
ance to apoptosis, and that enhanced apoptosis suscepti-
bility in response to inflammatory cytokines is not
diminished by TGF-β1 treatment.
We previously reported that fibroblasts from the lungs
of mice with established fibrosis had increased resistance
to apoptosis in association with decreased Fas mRNA,
decreased cellular Fas and decreased membrane-bound
Fas expression [13]. Moreover, we identified similar epi-
genetic modifications in the Fas promoter of fibroblasts
from bleomycin-treated mice and from IPF lung tissue
[13]. Consistently, several studies have reported that Fas
is minimally expressed by myofibroblasts within the fi-
broblastic foci of IPF lung tissue [18–20]. Moreover, pro-
moting expression of cell-surface Fas by treating normal
or IPF fibroblasts with inflammatory cytokines is suffi-
cient to enhance the susceptibility of these cells to apop-
tosis [19]. The mechanisms by which TGF-β1 and
matrix stiffness impact fibroblast Fas expression, which
may precede the epigenetic suppression in the earlier
phases of wound repair and fibrosis, have not been
elucidated.
Here, we found that Fas expression in normal lung
fibroblasts was regulated by substrate stiffness and by
the pro-fibrotic mediator TGF-β1. Lung fibrosis, both
in humans and in mice, is associated with increased
parenchymal stiffness which is not only thought to be
the consequence of extracellular matrix deposition
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and cross-linking, but is likely to contribute to the
persistence of fibrosis by directly supporting myofi-
broblast differentiation, matrix production and sur-
vival [23, 39–41]. Prior studies have reported that
increased substrate stiffness is associated with dimin-
ished basal rates of fibroblast apoptosis. In this study,
we show that substrates that recapitulate the stiffness
of fibrotic lung tissue promote fibroblast resistance to
FasL-induced apoptosis, and that the stiff matrix substrate
is sufficient to reduce fibroblast expression of Fas.
The mechanisms by which stiff ECM substrates affect
fibroblast phenotypes are likely to involve direct activa-
tion of mechanotransduction signaling pathways and ac-
centuated liberation of active TGF-β1 from its inactive/
latent form [26, 27]. Studies from our lab and others
have shown a critical role for Focal Adhesion Kinase
(FAK) in the regulation of myofibroblast phenotype in
vitro and lung fibrosis in vivo [30–32, 42]. Accordingly,
we anticipated the key role for FAK in TGF-β1 suppres-
sion of Fas transcription. However, we were surprised to
find that within the time course of our experiments, de-
creased Fas transcription did not significantly impact
expression of Fas on the cell surface. The absence of
change in cell-surface Fas expression is also consistent
with the failure of TGF-β1 to diminish the increased
fibroblast susceptibility to apoptosis conferred by treat-
ment with the combination of TNF-α/IFN-γ, which in-
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Fig. 5 a Normal lung fibroblasts in serum-free media were treated with the combination of TNF-α (10 ng/ml) and IFN-γ (50 U/ml) for the
indicated times up to 48 h. For the groups receiving inflammatory cytokines for 6–24 h, at the end of the exposure cells were washed with
PBS and replaced in serum free media. After 48 h, the cells were washed again with PBS and placed in serum free media with/without TGF-β1
(10 ng/ml) for another 24 h. Whole cell lysates were then assessed for Fas expression. Additional experiments were done to confirm the effects at
24 and 48 h, and the densitometry represents three independent experiments at those time points. b Normal lung fibroblasts were treated with/
without TNF-α (10 ng/ml) and IFN-γ (50 U/ml) for 24 h, washed with PBS and then exposed to Fas-activating antibody (Fas-Ab; 250 ng/ml) with/
without TGF-β1 (10 ng/ml) for 16 h. Whole cell lysates were assessed for PARP. Lane 7 is from control fibroblasts treated with the Fas-activating
antibody in combination with cycloheximide (CHX; 500 ng/ml) as a positive control for apoptosis
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The primary finding that TGF-β1 decreases Fas ex-
pression in fibroblasts is consistent with a recent report
showing that TGF-β1 mediated downregulation of
miR29c promotes suppression of Fas and increases fibro-
blast resistance to apoptosis [38]. However, our findings
with regards to the effects of TGF-β1 on cell surface Fas
expression differ from that study, which showed a rela-
tively small (approximately 20%) reduction. The reasons
for this discordance are not readily apparent, although
we suspect that these small differences may reflect ex-
perimental variability due to the fibroblast cell line used
and culture conditions. Allowing for this, we can con-
clude that the short-term effects of TGF-β1 on cell sur-
face Fas expression are, at most, mild. Notably, prior
studies have reported that fibrotic lung fibroblasts from
patients with IPF and from mice following intratracheal
bleomycin have decreased cell surface Fas when com-
pared to normal lung fibroblasts [13, 14]. When taken in
context with our data demonstrating that TGF-β1 de-
creases fibroblast transcription of Fas, we speculate over
longer durations the decreased Fas transcription does
lead to decreased surface receptor expression that is not
evident within the duration of our experimental design.
Further, it is possible that the effects of of TGF-β1 and
matrix stiffness become amplified when epigenetic mod-
ifications have already suppressed Fas expression.
We found that short-term treatment of normal fibro-
blasts with TGF-β1 promoted the release of sFas into the
cell culture media. This was prevented by treatment of fi-
broblasts with Brefeldin-A, suggesting that the sFas in the
cell culture media was due to active secretion of protein,
and not the result shedding or cleavage of the cell-surface
protein. Prior studies have shown that fibroblasts from pa-
tients with lung fibrosis release increased amounts of sFas
into their conditioned media [14]. Additionally, increased
levels of sFas have been identified in the bronchoalveolar
lavage fluid of patients with lung fibrosis [9]. The mechan-
istic role of sFas in the pathogenesis of lung fibrosis has
not been evaluated, but studies have shown that sFas can
function directly as an inhibitor of apoptosis [34, 43]. Ac-
cordingly, we speculate that TGF-β1-mediated secretion
of sFas may function to allow fibroblasts to evade inflam-
matory cell-mediated apoptosis in the early phases of
wound repair [7, 44]. We do note, however, that in our cell
culture model, secretion of sFas clearly did not diminish
fibroblast susceptibility to apoptosis when cell-surface Fas
expression was increased by treatment with TNF-α/IFN-γ.
This lack of an anti-apoptotic effect may reflect the dilu-
tion of sFas which would be expected to distribute evenly
within the cell culture media, thereby reducing the con-
centration of the soluble receptor at the cell surface. In
this cell culture model, the concentrations of Fas-Ab used
to induce apoptosis have been optimized to overcome any
potential dilutional effect, such that the relative ratio of
sFas secreted by cells is insufficient to neutralize the Fas-
Ab in the system.
Collectively, our studies and the existing literature suggest
a hierarchical hypothesis whereby different mechanisms
regulate fibroblast Fas expression during the evolution of
wound-repair and these changes may contribute to either
homeostatic repair or pathologic fibrosis depending on con-
text. We speculate that as an early response to injury, resi-
dent fibroblasts exposed to a normally compliant substrate
secrete sFas in response to TGF-β1, allowing the fibroblasts
to evade apoptosis due to FasL expressed on neighboring fi-
broblasts and inflammatory cells [44]. As the early repair-
response progresses, FAK-dependent transcriptional suppres-
sion due to a stiffening ECM substrate and continued TGF-
β1 exposure leads to decreased cell surface Fas expression
and decreased susceptibility to apoptosis, a potentially adap-
tive response that permits activated fibroblasts to persist in
an environment in which apoptotic stimuli are abundant. Ex-
posure to accumulating inflammatory cytokines then en-
hances cell surface Fas and enhances fibroblast susceptibility
to apoptosis in the context of homeostatic repair. If, however,
the temporal and spatial repair response becomes dysregu-
lated, as may occur in the context of continued or recurrent
injury or an aberrant inflammatory response, epigenetic mod-
ifications of the Fas promoter may “stabilize” an anti-
apoptotic phenotype and contribute to the aberrant repair re-
sponse recognized as fibrosis [13].
Conclusions
Fibroblast susceptibility to apoptosis is key to normal and
pathologic wound repair. Soluble and matrix-mediated
pro-fibrotic stimuli promote fibroblast resistance to apop-
tosis and decreased Fas transcription while stimulating
soluble Fas secretion. However, cell-surface Fas expression
is not significantly altered by TGF-β1 treatment and TGF-
β1 does not inhibit the enhanced fibroblast susceptibility
to apoptosis induced by inflammatory cytokines. Collect-
ively these data indicate that fibroblast expression of Fas
encompasses complex temporal and compartmental regu-
lation that may serve a variety of functions during the evo-
lution of injury-repair responses.
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